We boldly create novel and elegant CRISPR solutions to make a positive and profound impact on human health. From the very start we knew that CRISPR had the potential to cure the most complex genetic diseases, but limitations of the original CRISPR-Cas9 system prevented this vision from being fully realized. So we flipped the CRISPR script to first understand each genetic disease and then devise an optimal editing strategy. At EmendoBio, we’ve brought together a world class multifaceted team to evolve traditional CRISPR tools and create entirely new nucleases customized to any genetic disease. We come to work knowing every challenge we face can be overcome.
New York, United States
Founded in 2015
11-50 Employees
Working industry
Biotechnology
Type of company
-
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Biotechnology, Health Care, Pharmaceutical, Therapeutics
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Emendo Biotherapeutics operates in 1 country around the world
Get an overview of the locations of Emendo Biotherapeutics
Location
Country
State
City
Headquarter
United States
New York
New York
Some frequent questions that have been asked about Emendo Biotherapeutics
Where is Emendo Biotherapeutics located?
The company headquarter of Emendo Biotherapeutics is located in New York, New York, United States. It's worth noting, that the company may have more locations
How many employees does Emendo Biotherapeutics approximately have?
As of the latest available information Emendo Biotherapeutics has around 11-50 employees worldwide.
When was Emendo Biotherapeutics founded?
Emendo Biotherapeutics was founded in 2015
In which industries does Emendo Biotherapeutics mainly work?
The company Emendo Biotherapeutics has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Emendo Biotherapeutics
Life Edit
Morrisville, United States
11-50 Employees
2017
We are scientific pioneers with unlimited potential to cure genetic disease. We are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases. We are guided by curiosity, rigor, and integrity. We are pioneers with unlimited potential to cure genetic disease. Our highly innovative, next-generation platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. They were developed from a proprietary collection of non-pathogenic organisms and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Life Edit Therapeutics has joined ElevateBio’s portfolio of therapeutic, technology, and manufacturing companies and reimagined our identity. Our brand is an expression of our values, mission, and commitment to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable.
Alia Therapeutics
Italy
1-10 Employees
2018
We are developing next-generation gene editing medicines to cure rare genetic diseases at their roots by correcting inborn genetic errors directly in patients’ cells. Founded in 2018 based on the scientific discoveries of Anna Cereseto’s laboratory.
Editas Medicine
Cambridge, United States
101-250 Employees
2013
We are pioneering the possibilities of genomic medicines through gene editing. Our mission is to translate the power and potential of genome editing into a broad class of gene editing medicines that transform lives of people living with serious diseases. We are researching and developing both in vivo gene editing medicines, which edit genes inside the body, and ex vivo gene editing cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients. At Editas Medicine, we are pioneering the possible. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable genomic medicines for many diseases. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. We are motivated to deliver transformative medicines to the greatest number of patients around the world.
Scribe Therapeutics
United States
11-50 Employees
2017
Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.
CRISPR Therapeutics
Cambridge, United States
101-250 Employees
2013
We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.
Acrigen Biosciences
Berkeley, United States
1-10 Employees
2019
At Acrigen, we believe that gene editing will revolutionize medicine and bring hope to millions of patients suffering from genetic diseases. We are developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. Acrigen has discovered and engineered αCas and μCas, 2 families of novel CRISPR-Cas nucleases fine tuned for human gene editing.